CSL Limited

Australia Country flag Australia
Sector: Pharmaceuticals
Ticker: CSL
ISIN: AU000000CSL8
Factsheet Factsheet

Market multiple valuation of CSL Limited ( CSL | AUS)

The most common multiple used in the valuation of stocks is the P/Earnings NTM multiple (Price to Earnings). P/E relates the current share price with the market expectations in terms of Earnings Per Share. This multiple is used to compare a company's market value with its earnings. A company with a high P/Earnings NTM is considered to be overvalued; a company with a low P/Earnings NTM is considered to be undervalued.
The P/Earnings NTM ratio of CSL Limited is significantly higher than the median of its peer group: around 13.00. The company valuation of CSL Limited according to these metrics is way above the market valuation of its peer group.
The P/Earnings NTM ratio of CSL Limited is significantly higher than the average of its sector (Pharmaceuticals): 8.55. The company valuation of CSL Limited according to these metrics is way above the market valuation of its sector.
The P/Earnings NTM ratio of CSL Limited is significantly lower than its historical 5-year average: 34.2. The (current) company valuation of CSL Limited is therefore way below its valuation average over the last five years.

Valuation
P/E Last P/E (e) 2025P/E NTM
CSL LimitedFree trialFree trialFree trial
International PeersFree trialFree trialFree trial
Pharmaceuticals-0.117.658.55
S&P/ASX 20018.9716.0015.85
Australia-1.5611.9111.94
More...
Beta (Ref: S&P/ASX 200)
Levered betaUnlevered beta
1-Year0.790.72
2-Year0.540.49
3-Year0.590.54
More...
Stock Perf excl. Dividends (in AUD)
CSLS&P/ASX 200Rel. Perf.
Year-to-Date-8.8%1.1%-9.9%
1-Week5.1%3.5%1.6%
1-Month1.4%4.0%-2.6%
1-Year-6.9%8.6%-15.5%
3-Year-7.0%12.5%-19.5%
5-Year-16.0%58.7%-74.7%
More...
International Peers - CSL Limited
Company NameCtryMarket
Cap.
last (mUSD)
CSL LimitedAUS80 348
International Peers Median0.42
SanofiFRA-0.00
Amgen Inc.USA149 804
GlaxoSmithKline plcGBR-0.00
UCB S.A.BEL-0.00
Pfizer Inc.USA134 054
GPRV Analysis
Created with Highcharts 4.1.70/102/104/106/108/1010/10
CSL Limited
Intl. Peers
U.S Patents No. 7,882,001 & 8,082,201
More...
Net Sales Chart
Created with Highcharts 4.1.7Millions USD201920202021202220232024 (e)2025 (e)2026 (e)2027 (e)0k10k20k30k
More...
Quotes Chart

1-Year Rebased Stock Chart

  • CSL Limited
  • S&P/ASX 200
Created with Highcharts 4.1.7Jan '25Sep '24May '25-20%-10%0%10%20%
More...

Did you know ?

Multiples charts provide an effective way to quickly analyze a company's valuation over a period of time, and compare it against the valuation of another company, a personal list, or a market index.

About Market Multiples

Many methods can be used to value a company. In reality, business valuation is often a combination of these different approaches. One of the most widely used quantitative methods is the market multiples method. The market valuation is utilized generally as a primary market input, to provide an objective starting point for the valuation. Put simply, this method multiplies the sales or profits of a business by an industry averaged multiplier to calculate the Market Value of the business.
Current multiples include:
- Historical multiples based on standardized financials for the last completed fiscal period: Last, Last Twelve Months (LTM);
- Forward multiples based on consensus estimates for the current fiscal period and next ones: Next Twelve Months (NTM), FY0, FY1.
Current multiples based on per-share metrics (such as earnings per share or book value per share) are calculated using the last closing price, while current multiples based on company-level metrics (such as net sales, EBIT or EBITDA) are calculated using the current market cap or EV (Enterprise Value).